There are multiple, well-proven and safe approaches to treating type II diabetes and metabolic dysfunction. Fortunately, these different approaches can be used individually, or in conjunction with one another. When viewed as single therapies however, it is OsteoStrong that performs the best compared to the other standards of care in the reduction of HbA1c (long term blood glucose measures).
Treatment costs exceed $322 billion per year.
Type II diabetes (T2D) and pre-diabetes, also known as metabolic disease, affects nearly 100 million Americans (1 in 3 people). †
20% of all healthcare dollars are spent on metabolic disease.